Free Trial
NASDAQ:ATYR

Atyr PHARMA Q1 2025 Earnings Report

Atyr PHARMA logo
$4.75 +0.28 (+6.26%)
Closing price 04:00 PM Eastern
Extended Trading
$4.79 +0.04 (+0.82%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atyr PHARMA EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.19
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Atyr PHARMA Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atyr PHARMA Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atyr PHARMA's Q1 2025 earnings is scheduled for Tuesday, August 12, 2025

Earnings Documents

Atyr PHARMA Earnings Headlines

Analysts Set Atyr PHARMA INC (NASDAQ:ATYR) PT at $18.60
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Atyr PHARMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atyr PHARMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atyr PHARMA and other key companies, straight to your email.

About Atyr PHARMA

Atyr PHARMA (NASDAQ:ATYR), Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View Atyr PHARMA Profile

More Earnings Resources from MarketBeat